COVID-19 roundup: Global cases on decline, latest recommendations by WHO

April 26, 2022 06:04 PM AEST | By Aditi Sarkar
Follow us on Google News:


  • Global COVID-19 cases are falling since mid-March
  • China’s capital city Beijing began three rounds of COVID-19 testing for all residents of its largest district, Chaoyang, on Monday
  • WHO has suggested Pfizer's oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) for high-risk patients

Globally, there has been a decline in the number of COVID-19 cases since mid of March this year. Last week, global COVID-19 cases dropped by 21.33%. As of 25 April 2022, the global COVID-19 caseload stood at 507,501,771, having claimed 6,220,390 lives. So far, 11.32 billion vaccine doses have been administered.  

In the last 24 hours, France reported the highest number of confirmed cases (58,954), followed by Italy (56,848) and Japan (38,450). According to total cumulative cases, the USA tops the list (80.17 million), followed by India (43.06 million) and Brazil (30.34 million).  

As of 25 April 2022, Australia recorded 361,716 active cases of the COVID-19 virus, with a total tally of 5,512,954 confirmed cases.  

China enrolls mass testing

After China reported 34.35% weekly increment in COVID-19 cases, Beijing began three rounds of Covid-19 testing for all residents of its largest district, Chaoyang, on Monday. Authorities in Chaoyang have ordered residents and workers to undergo testing this week after Beijing warned that the virus had spread "silently" throughout the city for almost a week before being discovered. 

What does WHO suggest on COVID-19 medications?

Recently, the World Health Organisation (WHO) made a significant recommendation regarding COVID-19 therapeutics. It has suggested nirmatrelvir and ritonavir, available in the market as Paxlovid, as the best therapeutic choice for non-severe COVID-19 patients with the highest risk of hospital admission. This may include unvaccinated, older, and immunosuppressed patients. 

WHO has recommended Pfizer's oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) for high-risk patients on the basis of fresh data obtained after two randomized controlled trials on a total of 3078 patients who had mild or moderate COVID-19 infection.  

The WHO is worried that low- and middle-income countries will again be the last in the queue to secure this treatment, as in the case of the COVID-19 vaccine. In this regard, here are the major obstacles:

Therefore, the WHO states that Pfizer should make its pricing and negotiations more transparent and expand the geographic scope of its licence with the Medicines Patent Pool. It will enable the production of the medicine by generic manufacturers and make it available sooner and at lower prices. 

Following a recent clinical trial data, the WHO suggests the use of remdesivir in mild or moderate COVID-19 patients, who are at high risk of hospitalization.

How are covid mandates affecting cinema companies? 


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK